Delcath Systems Inc Up 0.86% To $4.70 After Earnings Beat

Delcath Systems Inc (DCTH) said before open Tuesday that it lost $0.48 per share in quarter four 2023.

On the revenue line, the company reported $539 thousand, missing estimates by $1,000.00.

In the same quarter a year ago, the company lost $0.86 per share on revenue of $639 thousand.

The stock is up 0.86% to $4.70 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Delcath Systems Inc has performed a little below average during the past few months. Before the report, Delcath Systems Inc received a Long-Term Technical Rank by InvestorsObserver of 43, putting it in the bottom half of stocks. The firm set a 52-week low on November 14, 2023 at $2.25 and set a 52-week high on May 31, 2023 at $7.99.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.